Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.
Andre Goy, MD, MS, chairman and director, John Theurer Cancer Center (JTCC), chief, Division of Lymphoma, discusses the significance of becoming a National Cancer Institute (NCI)-designated cancer center.
In May 2019, John Theurer Cancer Center was approved to become a member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center Consortium. The idea of having NCI-designated institutions is to cover the whole spectrum of research, treatment, cancer prevention, survivorship, and education. Of what is now 49 nationwide institutions under the NCI umbrella, 16 are participating in this consortium. These institutions have a track record of proven excellence, as such, bringing them together bolsters the NCI’s initial mission, Goy explains.
JTCC is honored to receive an NCI designation and be part of the consortium, Goy adds. It will have a huge impact on patients because it exposes them to a broader range of clinical trial opportunities and essentially guarantees the best available care. Researchers from these centers granted this designation will also work on addressing cancer disparities.